Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Mayzent 0.25 mg film-coated tablets {equilateral_black_triangle}

Active Ingredient:
siponimod fumaric acid
Company:  
Novartis Pharmaceuticals UK Ltd See contact details
ATC code: 
L04AA42
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Product Information Live Chat HCP Med Info
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

Mayzent (siponimod) - Patient & Caregiver Medical Information Guide - for patients and caregivers

This guide contains important information about MAYZENT® (siponimod) dosing, side effects and their potential risks, including guidance on pregnancy
{pdf_link}

Mayzent (siponimod) - Pregnancy Reminder Card - for patients

This Pregnancy Reminder Card contains information for female patients of childbearing potential
{pdf_link}

Mayzent (siponimod) - Prescriber Checklist - For Healthcare Professionals

{healthcare_pro_orange} For Healthcare Professionals
This guide provides essential information on the most important risks associated with Mayzent and the activities required to minimise these risks. It is advised that this guide is read alongside the summary of product characteristics

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Novartis Pharmaceuticals UK Ltd
Company image
Address
2nd Floor, The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ
Telephone
+44 (0)1276 692 255
Medical Information Direct Line
+44 (0)1276 698 370
Medical Information e-mail
[email protected]
Customer Care direct line
+44 (0)845 741 9442
E-mail
[email protected]